BTIG Reaffirms Their Buy Rating on Freeline Therapeutics Holdings (FRLN)

BTIG analyst Yun Zhong reiterated a Buy rating on Freeline Therapeutics Holdings (FRLNResearch Report) yesterday and set a price target of $3.00. The company’s shares closed yesterday at $0.68.

Zhong covers the Healthcare sector, focusing on stocks such as Voyager Therapeutics, Amicus, and Sarepta Therapeutics. According to TipRanks, Zhong has an average return of -16.9% and a 35.94% success rate on recommended stocks.

Freeline Therapeutics Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $9.00.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $2.87 and a one-year low of $0.60. Currently, Freeline Therapeutics Holdings has an average volume of 26.79K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Freeline Therapeutics Holdings PLC is a clinical stage, systemic AAV-based gene therapy company. The company is developing therapies for Haemophilia B, Fabry disease, Gaucher disease, and other diseases.

Read More on FRLN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More